Breaks Categories: News

ThursdayJul 29, 2021 12:57 pm

NetworkNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Completes Financial Filing Requirements, Upgraded by OTC Markets

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer hearing health technology space, has completed the filing of all required financial reports with OTC Markets and has submitted an attorney opinion letter, and has now been officially declared Pink Current. In order to receive that listing, the company filed all  annual disclosure statements and the financial report for its first quarter ending March 31, 2021, with OTC Markets. According to the announcement, InnerScope is working to meet all requirements to upgrade to and trade on the OTCQB as soon as possible. “InnerScope is very pleased to announce…

Continue Reading

ThursdayJul 29, 2021 12:26 pm

NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other health care providers in a live and hands-on setting. The Institute’s emphasis will focus on educating health care providers about OSA, Vivos’ treatments for OSA within their practice areas and providing training on Vivos’ related practice management tools…

Continue Reading

ThursdayJul 29, 2021 12:02 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Study Results Indicating DehydraTECH-CBD Lowers Blood Pressure

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released results from its recent human clinical study focused on evaluating DehydraTECh(TM)-processed cannabidiol (“CBD”) for potential application against hypertension. The study, HYPER-H21-1, indicated a rapid, sustained drop in blood pressure with DehydraTECH-CBD as well as excellent tolerability. The partial results will be followed by more complete results after additional BP subset analyses and other data analyses are completed. According to the study’s lead investigator, Dr. Phil Ainslie, the early results appear to be extremely promising as blood pressure was reduced across both male and female volunteers and supported earlier findings…

Continue Reading

ThursdayJul 29, 2021 11:03 am

NetworkNewsBreaks – Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Begins Trading on NASDAQ under KAVL Ticker

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products manufactured by Bidi(R) Vapor LLC, began trading its common stock on the Nasdaq Capital Market at market open today, July 29, 2021. The company is trading under the ticker symbol KAVL. In the announcement, the company acknowledged key players that had provided support for the company as it made this transition; those key players include BTIG, Maxim, and Ladenburg Thalmann & Co. Kaival Brands works with Bidi Vapor to provide recreational, noncombusted alternatives for adult cigarette smokers while strongly opposing all illegal underage tobacco use by minors. The company is…

Continue Reading

ThursdayJul 29, 2021 10:48 am

NetworkNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Enters Strategic Alliance Focused on Recovery of Isotopes Needed for Emerging Cancer Therapeutics

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, is partnering with RadTran LLC to evaluate the recovery of thorium, and potentially radium, from UUUU’s existing rare earth carbonate and uranium process streams for use in producing medical isotopes for emerging targeted alpha therapy (“TAT”) cancer therapeutics. The partnership is outlined in a strategic alliance agreement and has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain. RadTran is a Colorado-based tech-development company working on closing critical gaps in the procurement of medical isotopes for…

Continue Reading

ThursdayJul 29, 2021 10:48 am

NetworkNewsBreaks – AmpliTech Group Inc. (NASDAQ: AMPG) Featured in Stock2Me Podcast, Secures $0.5M in Follow-On Orders

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art components and semiconductor chips for satellite and 5G communications networks, defense, space, and other commercial applications, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. AMPG’s Director of Communications Shan Sawant joined the latest episode to discuss AmpliTech’s business model and offer an overview of the company’s proven, decades-long track record of providing vital radio frequency components to an impressive list of clients. “AmpliTech provides high-quality radio frequency (‘RF’) components that allow for high performance, low noise wireless connections in…

Continue Reading

ThursdayJul 29, 2021 10:19 am

NetworkNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces LOI, Enters Promising Australian Medical Cannabis and OTC CBD Space

Flora Growth (NASDAQ: FLGC), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, as signed a Letter of Intent (“LOI”) with Evergreen Pharmacare Pty Ltd. Evergreen is a licensed importer and distributor of medical cannabis products based in Australia, and the LOI calls for Flora to provide raw and finished medical cannabis products for medical cannabis patients. Flora plans to ship the medical-grade cannabis products after the company obtains the correct export licenses and completes its first commercial harvest. The LOI is the second that Flora has signed since recent changes in Colombian law allow the company to sell…

Continue Reading

ThursdayJul 29, 2021 9:58 am

NetworkNewsBreaks – Friendable Inc. (FDBL) Featured in SmallCapVoice.com Interview

Friendable (OTC: FDBL), a mobile technology and marketing company, was featured in a new interview with SmallCapVoice.com Inc. (“SCV”). Friendable CEO Robert A. Rositano Jr. joined SCV's Stuart Smith to discuss the timely launch of the company's version 2.0 of the Fan Pass livestream artist platform and its aggressive strategy to achieve “immense scalability.” Rositano Jr. explains that the Fan Pass app is a platform and true artist partner that enables authentic interaction between artists and their fans. The app’s features are tailored to both the artist and the fan, catering to individual needs and wants, including a suite of…

Continue Reading

ThursdayJul 29, 2021 9:50 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has received approval for its common shares to trade on the NYSE American LLC stock exchange. According to the announcement, the company anticipates that trading to begin on or about Aug. 5, 2021; the company will trade on the exchange using the symbol CYBN. The company will continue to list its common shares in Canada on the NEO Exchange under the symbol CYBN and on the Frankfurt Stock Exchange under the symbol R7E1. Shareholders are encouraged to check their accounts to make sure that change in exchange…

Continue Reading

ThursdayJul 29, 2021 9:49 am

NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has reported its interim financial results; the results cover the three- and nine-month period ended May 31, 2021. Highlights of the report include Tryp’s collaboration with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School; the two companies will work together to conduct a Phase 2a clinical trial for fibromyalgia that is the first Phase 2 study evaluating the efficacy of a psychedelic compound for the indication. In addition, Tryp also partnered with the…

Continue Reading